# Nimble Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nimble-therapeutics

- Industry: Biotechnology
- Headquarters: Madison, US
- Website: www.nimbletherapeutics.com
- Total disclosed funding: $10M
- Latest round: Series A (Apr 2, 2019)
- Investors on record: 2

## About

Based in Wisconsin, US, and founded in 2019, Nimble Therapeutics, Inc. operates as a biotech company that focuses on developing oral therapies for immune-mediated diseases. Nimble leverages its proprietary discovery engine to create therapies that replicate the benefits of established treatments. In December 2024, AbbVie agreed to acquire Nimble Therapeutics, Inc. from Roche Venture Fund and Telegraph Hill Partners for USD 200 million in cash.

Nimble Therapeutics specializes in advanced drug discovery technologies, focusing primarily on immunology and therapeutics. The company is dedicated to developing breakthrough medicines through its proprietary platforms, which facilitate the identification and optimization of novel therapeutic candidates. These technologies aim to address a variety of diseases by enhancing the therapeutic efficacy and safety profiles of drug candidates. Nimble Therapeutics serves a diverse client base, which includes pharmaceutical companies and research institutions seeking to advance their drug development pipelines.

Nimble Therapeutics generates revenue through strategic partnerships and collaborations with major pharmaceutical firms. The transaction structure typically involves B2B arrangements, where clients engage the company for its drug discovery services and technologies.

## Funding rounds

- Series A, Apr 2, 2019, $10M — Telegraph Hill Partners, Roche Venture Fund

## Investors

- Telegraph Hill Partners (https://capitalatlas.ai/funds/telegraph-hill-partners) — Series A
- Roche Venture Fund (https://capitalatlas.ai/funds/roche-venture-fund) — Series A